Calcium channel blocker in myotonic dystrophy type 1 (cap DM1)

Active Grant Awarded Last action

Award ID
R01FD008510
Recipient
Awarding agency
Obligated
$1,335,086

Award facts

Assistance listing
93.103 Food and Drug Administration Research
Completion date 4% complete
Funding agency
Office of Medical Products and Tobacco Food and Drug Administration, Department of Health and Human Services
Place of performance
Rochester, NY 14611, USA

Award details come from USAspending.gov.

About this award

The Department of Health and Human Services Food and Drug Administration awarded Grant R01FD008510 to the University of Rochester on September 23, 2026, with $1.335086 million obligated under Assistance Listing 93.103, Food and Drug Administration Research. The agency's structured record also lists the Office of Medical Products and Tobacco as an alternate name. The award funds a single-center, open-label clinical trial, "Calcium Channel Blocker in Myotonic Dystrophy Type 1 (CAP DM1)," assessing the safety and tolerability of daily amlodipine at two doses, 5 mg and 10 mg, in 20 subjects with myotonic dystrophy type 1. The project rests on the premise that excess calcium entry contributes to DM1-associated myopathy, and the source states that no FDA-approved therapies exist for the disease. Place of performance is Rochester, New York 14611, and the ultimate completion date is June 30, 2030.

Description

Abstract
Myotonic dystrophy type 1 (DM1) causes progressive muscle weakness, MYOTONIA (delayed relaxation of muscle), cardiac conduction delay, GI dysmotility due to smooth muscle involvement, and respiratory weakness, resulting in premature death. There are no FDA-approved therapies. The genetic lesion in DM1 is an unstable expanded CTG repeat in dmpk. The disease results from RNA toxicity, a process whereby RNA with expanded CUG repeats forms nuclear foci that sequester splicing factors in the muscleblind-like (MBNL) family. This resulting dysregulation of alternative splicing affects several genes involved in excitation- contraction coupling. Among these, MIS-splicing of CLC-1 chloride channel leads to repetitive action potentials (MYOTONIA), whereas MIS-splicing of CAV1.1 calcium channel leads to increased calcium entry with each action potential. When combined together in mice, this BI-channelopathy resulted in aggravation of MYOTONIA, transient weakness (temporary electric inexcitability), progressive muscle impairment, and marked reduction of lifespan. The survival of BI-channelopathy mice is dramatically improved by oral feeding of the calcium channel blocker amlodipine. Amlodipine also improved survival, strength, and MYOTONIA in a severe DM1 model, in which expanded CUG-repeat RNA is expressed on a background of MBNL1 gene deletion. These results support a contributory role for excess calcium entry in DM1-associated myopathy, and suggest that CA2+ channel modulation is a potential therapeutic strategy. Here, we propose a single-center open-label clinical trial ("calcium channel blocker in myotonic dystrophy type 1 -cap DM1") assessing the safety and tolerability of daily amlodipine at two doses (5 and 10 MG) in 20 subjects with DM1. Amlodipine was selected because of its (1) wide use and favorable safety profile for treating hypertension; (2) lack of adverse effects on the cardiac conduction system; and (3) long half-life, permitting once-daily dosing. However, tolerability needs to be established, and may differ in DM1 from the general population, because DM1 is associated with lower blood pressure, likely related to smooth muscle involvement. A 2-week titration period will be followed by an 8-week treatment period. At week 6, we will randomize half the subjects to a blinded phase at either continued 5 or 10MG amlodipine daily. Primary outcomes include safety and tolerability, blood pressure, and adverse events. Secondary outcomes include electrophysiologic measures of transient weakness and MYOTONIA, clinical assessments of muscle strength and function, and patient-reported outcomes (pain, fatigue, GI symptoms). The electrophysiologic studies will provide objective evidence of calcium blockade through CAV1.1. This study, designed with input from our patient partners, will provide an initial assessment of amlodipine safety and CAV1.1 blocking activity at two dose levels in people with DM1, and inform a subsequent randomized controlled trial to evaluate longer-term efficacy. If effective, amlodipine will be the first orally administered drug to modify DM1 disease progression, globally available at low cost, with immediate impact on clinical practice.

Quick answers

Who received award R01FD008510?

R01FD008510 was awarded to University Of Rochester by FDA Office of Acquisition and Grant Services (Food and Drug Administration) on September 23, 2026.

How much is award R01FD008510 worth?

$1,335,086 has been obligated on R01FD008510.

Which agency awarded R01FD008510?

FDA Office of Acquisition and Grant Services (Food and Drug Administration) awarded R01FD008510, with funding from Office of Medical Products and Tobacco (Food and Drug Administration).

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award